EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Exploring Ceramide C16:0 as a Novel Biomarker and Therapeutic Target for Atherosclerosis

Tingting Chen iD, Lingling Xie, Yan Zhao iD, Yuxin Shang, Yuqing Pan iD, Weiqiang Wang, Wei Mao iD

Journal of the American Heart Association · 20.01.2026 · 15 (2)

DOI: 10.1161/jaha.125.044903 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Heart Association, erschienen am 20.01.2026. Verfasst von Tingting Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine Zhejiang Chinese Medical University Zhejiang Hangzhou China. Hauptthemen laut MEDLINE: Atherosclerosis, Ceramides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ceramide C16:0, a key metabolite in sphingolipid metabolism, has been found to play a critical role in the pathogenesis of atherosclerosis. This comprehensive review elucidates the pathogenic mechanism by which ceramide C16:0 contributes to the development of atherosclerosis, including activating inflammatory responses, inducing insulin resistance, impairing endothelial function, disrupting mitochondrial homeostasis, and exacerbating endoplasmic reticulum stress. Clinical evidence demonstrates that the elevated levels of plasma ceramide C16:0 exhibit a strong correlation with an increased risk of cardiovascular events, supporting its potential utility as an independent prognostic biomarker. Inhibition of ceramide C16:0 synthesis or blockade of its receptors demonstrates promising therapeutic potential. Future research should focus on developing specific inhibitors, refining cardiovascular risk assessment models, and exploring integrative treatment strategies, aiming to offer new strategies for preventing and treating atherosclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisCeramidesHumansBiomarkersAnimalsInsulin ResistanceEndoplasmic Reticulum Stress

Stichwörter der Autor:innen

atherosclerosisceramide C16:0endoplasmic reticulum stressendothelial cells dysfunctioninflammatory responseinsulin resistancemitochondrial homeostasis

Substanzen

CeramidesBiomarkers

Autor:innen und Institutionen

  • The First School of Clinical Medicine Zhejiang Chinese Medical University Zhejiang Hangzhou China.
  • Zhejiang Key Laboratory of Integrative Chinese and Western Medicine for Diagnosis and Treatment of Circulatory Diseases Zhejiang Hospital (Affiliated Zhejiang Hospital, Zhejiang University School of Medicine) Zhejiang H…
  • Zhejiang Engineering Research Center for Precise Diagnosis and Innovative Traditional Chinese Medicine for Cardiovascular Diseases Zhejiang Hospital (Affiliated Zhejiang Hospital, Zhejiang University School of Medicine)…
  • Department of Cardiology Zhejiang Hospital (Affiliated Zhejiang Hospital, Zhejiang University School of Medicine) Zhejiang Hangzhou China.

ORCID-Profile: Tingting Chen, Yan Zhao, Yuqing Pan, Wei Mao

Zitieren

APA

Chen, T., Xie, L., Zhao, Y., Shang, Y., Pan, Y., Wang, W., & Mao, W. (2026). Exploring Ceramide C16:0 as a Novel Biomarker and Therapeutic Target for Atherosclerosis. Journal of the American Heart Association, 15(2). https://doi.org/10.1161/jaha.125.044903

Vancouver

Chen T, Xie L, Zhao Y, Shang Y, Pan Y, Wang W, et al. Exploring Ceramide C16:0 as a Novel Biomarker and Therapeutic Target for Atherosclerosis. Journal of the American Heart Association. 2026;15(2). doi:10.1161/jaha.125.044903

BibTeX
@article{Chen2026,
  author = {Chen, Tingting and Xie, Lingling and Zhao, Yan and Shang, Yuxin and Pan, Yuqing and Wang, Weiqiang and Mao, Wei},
  title = {Exploring Ceramide C16:0 as a Novel Biomarker and Therapeutic Target for Atherosclerosis},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {2},
  doi = {10.1161/jaha.125.044903}
}
Kostenlos starten →